Lexicon Pharmaceuticals, Inc. (LXRX)
1.79
-0.03
(-1.65%)
USD |
NASDAQ |
Nov 13, 16:00
1.80
+0.01
(+0.56%)
After-Hours: 19:59
Lexicon Pharmaceuticals Enterprise Value : 672.85M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 672.85M |
| November 12, 2026 | 686.19M |
| November 11, 2026 | 708.44M |
| November 10, 2026 | 703.99M |
| November 09, 2026 | 686.19M |
| November 06, 2026 | 668.40M |
| November 05, 2026 | 592.75M |
| November 04, 2026 | 534.90M |
| November 03, 2026 | 526.00M |
| November 02, 2026 | 517.10M |
| October 30, 2026 | 508.20M |
| October 29, 2026 | 534.90M |
| October 28, 2026 | 537.13M |
| October 27, 2026 | 534.90M |
| October 26, 2026 | 521.55M |
| October 23, 2026 | 508.20M |
| October 22, 2026 | 539.35M |
| October 21, 2026 | 570.50M |
| October 20, 2026 | 579.40M |
| October 19, 2026 | 566.05M |
| October 16, 2026 | 552.70M |
| October 15, 2026 | 610.55M |
| October 14, 2026 | 588.30M |
| October 13, 2026 | 592.75M |
| October 12, 2026 | 610.55M |
| Date | Value |
|---|---|
| October 09, 2026 | 623.90M |
| October 08, 2026 | 659.50M |
| October 07, 2026 | 659.50M |
| October 06, 2026 | 655.05M |
| October 05, 2026 | 650.60M |
| October 02, 2026 | 686.19M |
| October 01, 2026 | 686.19M |
| September 30, 2026 | 710.67M |
| September 29, 2026 | 705.11M |
| September 28, 2026 | 714.01M |
| September 25, 2026 | 667.29M |
| September 24, 2026 | 696.21M |
| September 23, 2026 | 785.20M |
| September 22, 2026 | 838.59M |
| September 21, 2026 | 776.30M |
| September 18, 2026 | 780.75M |
| September 17, 2026 | 774.08M |
| September 16, 2026 | 767.40M |
| September 15, 2026 | 762.95M |
| September 14, 2026 | 749.61M |
| September 11, 2026 | 758.50M |
| September 10, 2026 | 767.40M |
| September 09, 2026 | 825.25M |
| September 08, 2026 | 860.84M |
| September 04, 2026 | 865.29M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Bristol Myers Squibb Co. | 161.88B |
| ANI Pharmaceuticals, Inc. | 1.807B |
| Corcept Therapeutics, Inc. | 7.615B |
| Veru, Inc. | 12.53M |
| Johnson & Johnson | 715.26B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.00M |
| Revenue (Quarterly) | 11.25M |
| Total Expenses (Quarterly) | 25.26M |
| EPS Diluted (Quarterly) | -0.0315 |
| Gross Profit Margin (Quarterly) | 98.45% |
| Profit Margin (Quarterly) | -124.5% |
| Earnings Yield | -8.35% |
| Normalized Earnings Yield | -7.961 |